Prof. Mahlangu gives a brilliant presentation on the advantages of Non-Factor Replacement Therapy for People with Haemophilia; both with Inhibitors and without Inhibitors.
The webinar covers:
the unmet needs in Haemophilia
gives an overview of new and novel therapies to address these unmet needs
presents the efficacy, safety, pharmacokinetic and QoL (Quality of Life) data of Emicizumab from Haven Studies